@destefanomd.bsky.social
Reposted
New in #JCO Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial #MCC #openaccess #oncsky ascopubs.org/doi/10.1200/...
Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial | Journal of Cli...
PURPOSETo investigate whether intermittent treatment after an induction phase of first-line
schedule of fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus panitumumab (PAN)
prevents or delays the...
ascopubs.org
November 24, 2024 at 6:05 PM
New in #JCO Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial #MCC #openaccess #oncsky ascopubs.org/doi/10.1200/...